المؤلفون: Charles Naltet, Youssef Oulkhouir, Gérard Zalcman, Solenn Brosseau

المصدر: Bulletin du Cancer. 102:S27-S33

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Fulvestrant, Bevacizumab, Cetuximab, business.industry, Cancer, Hematology, General Medicine, medicine.disease, Resistance mutation, respiratory tract diseases, Metastasis, Internal medicine, medicine, ROS1, Radiology, Nuclear Medicine and imaging, Progression-free survival, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::aa9d88f49f5c7646540952263237457cTest
https://doi.org/10.1016/s0007-4551Test(15)31215-7

المؤلفون: Solenn, Brosseau, Youssef, Oulkhouir, Charles, Naltet, Gérard, Zalcman

المصدر: Bulletin du cancer. 102(6 Suppl 1)

مصطلحات موضوعية: Lung Neoplasms, Antineoplastic Agents, Hormonal, Estradiol, Cetuximab, Angiogenesis Inhibitors, Cell Cycle Checkpoints, Antibodies, Monoclonal, Humanized, Disease-Free Survival, Translocation, Genetic, Bevacizumab, ErbB Receptors, Drug Resistance, Neoplasm, Carcinoma, Non-Small-Cell Lung, Mutation, Humans, Molecular Targeted Therapy, Fulvestrant, Protein Kinase Inhibitors

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::0126ee44d326450425fc81ef188eb979Test
https://pubmed.ncbi.nlm.nih.gov/26118873Test